DarioHealth Corp. closed its underwritten public offering of 1,450,000 common shares at $3.10 per share with gross proceeds of about $4.5 million.

The company plans to use the net proceeds for its products' commercialization efforts, including increased marketing and production expenses, and for general working capital purposes.

Aegis Capital Corp. acted as the sole book-running manager for the offering. Migdal Investment Banking served as Dario's Israeli adviser in the offering.